Remedium Capital Partners, LLC — 13F Holdings & Portfolio
CIK 2104501 · latest 13F-HR filed 2026-05-19
Remedium Capital Partners, LLC manages $281.2M in 13F-reported U.S. long-equity assets across 6 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are ORKA (27.31%), SYRE (26.13%), DMRA (18.84%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 0 new positions, exited 0, added to 0, and trimmed 2.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$281.2M
Long-equity book
6
Distinct positions
2026-03-31
Filed 2026-05-19
+0 / −0 / ↑0 / ↓2
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Oruka Therapeutics Inc | ORKA | 687604108 | $76.8M | 27.31% | 1,565,661 | SH |
| 2 | Spyre Therapeutics Inc | SYRE | 00773J202 | $73.5M | 26.13% | 1,456,231 | SH |
| 3 | Damora Therapeutics Inc | DMRA | 36322Q206 | $53.0M | 18.84% | 2,045,473 | SH |
| 4 | Apogee Therapeutics Inc | APGE | 03770N101 | $49.1M | 17.47% | 583,591 | SH |
| 5 | Jade Biosciences Inc | JBIO | 008064206 | $22.2M | 7.88% | 1,577,750 | SH |
| 6 | Crescent Biopharma Inc | CBIO | 38000Q201 | $6.6M | 2.36% | 361,250 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | $319.8M | 6 | 0002104501-26-000008 |
| 2026-03-31 | 2026-05-19 | $281.2M | 6 | 0002104501-26-000010 |
| 2025-12-31 | 2026-02-12 | $170.2K | 6 | 0002104501-26-000004 |